Cargando…

Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy

BACKGROUND: Cancerous cells usually exhibit increased aerobic glycolysis, compared with normal tissue (the Warburg effect), making this pathway an attractive therapeutic target. METHODS: Cell viability, cell number, clonogenic assay, reactive oxygen (ROS), ATP, and apoptosis were assayed in MCF-7 tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golding, J P, Wardhaugh, T, Patrick, L, Turner, M, Phillips, J B, Bruce, J I, Kimani, S G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749566/ https://www.ncbi.nlm.nih.gov/pubmed/23860536 http://dx.doi.org/10.1038/bjc.2013.391

Ejemplares similares

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro
por: Etminan, N, et al.
Publicado: (2011)

Early neoplastic and metastatic mammary tumours of transgenic mice detected by 5-aminolevulinic acid-stimulated protoporphyrin IX accumulation
por: Dorward, A M, et al.
Publicado: (2005)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells
por: Sinha, A K, et al.
Publicado: (2006)

A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy
por: Castano, A P, et al.
Publicado: (2006)

Peripheral neural cell sensitivity to mTHPC-mediated photodynamic therapy in a 3D in vitro model
por: Wright, K E, et al.
Publicado: (2009)

Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen
por: Reginato, E, et al.
Publicado: (2013)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
por: Gottlieb, D J, et al.
Publicado: (2006)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells
por: Ortel, B, et al.
Publicado: (2002)

Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid
por: Niedre, M J, et al.
Publicado: (2005)

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells
por: Thiel, U, et al.
Publicado: (2011)

CD8(+) T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4(+) T cells and dependent on natural killer cells
por: Kabingu, E, et al.
Publicado: (2007)

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells
por: Valenzuela, M, et al.
Publicado: (2014)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy
por: Duanmu, J, et al.
Publicado: (2011)

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007)

Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells
por: Laptev, R, et al.
Publicado: (2006)

Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin
por: Korbelik, M, et al.
Publicado: (2007)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
por: Huynh, C K, et al.
Publicado: (2006)

Protoporphyrin IX enhancement by 5-aminolaevulinic acid peptide derivatives and the effect of RNA silencing on intracellular metabolism
por: Bourré, L, et al.
Publicado: (2009)

Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin
por: Dietze, A, et al.
Publicado: (2005)

Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling
por: Wei, L-H, et al.
Publicado: (2007)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
por: Byrne, A T, et al.
Publicado: (2009)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
por: Šímová, J, et al.
Publicado: (2011)

Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer
por: de Souza, Ana Luiza Ribeiro, et al.
Publicado: (2016)

Comparative analysis of xanafide cytotoxicity in breast cancer cell lines
por: Alami, N, et al.
Publicado: (2007)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_h7rr8dab5d4vqp6kllvklloeb0